Welcome to our dedicated page for Oncorus news (Ticker: ONCR), a resource for investors and traders seeking the latest updates and insights on Oncorus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncorus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncorus's position in the market.
Oncorus, Inc. (Nasdaq: ONCR) announced a public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares. This offering is underwritten by Jefferies, Evercore ISI, and Piper Sandler. The public offering price remains undetermined. The registration statement has been filed with the SEC but is not yet effective. Proceeds from this offering may be used to advance Oncorus’ innovative viral immunotherapy programs, including ONCR-177, aimed at improving cancer treatment outcomes.
Oncorus has published encouraging preclinical findings for its lead oncolytic virus candidate, ONCR-177, showing significant antitumor activity in various models. The study highlights ONCR-177's unique combination of five immunomodulatory transgene payloads and retention of γ34.5, which enhances systemic immunity. Initial safety data from an ongoing Phase 1 trial suggests potential for effective treatment of solid tumors. Oncorus aims to report interim data from this trial in the second half of 2021, continuing its development in the field of cancer immunotherapy.
Oncorus, a clinical-stage biopharmaceutical company, has signed a 15-year lease for an 88,000 square foot GMP manufacturing facility in Andover, Massachusetts. This site will support Oncorus' pipeline of viral immunotherapies, including the lead candidate ONCR-177, currently in Phase 1 trials. The first phase of the facility's buildout is expected to be completed in late 2021, with full operations projected by early 2023.
The investment underscores Oncorus' commitment to growth and the advancement of innovative cancer therapies.
Oncorus, Inc. (Nasdaq: ONCR) has announced the appointment of Scott Canute to its Board of Directors, enhancing its strategic direction as the company progresses its viral immunotherapies pipeline. Canute brings nearly 40 years of biopharmaceutical experience, having held significant roles at Genzyme and Eli Lilly. Under his guidance, Oncorus aims to bolster in-house manufacturing capabilities while advancing its lead candidate, ONCR-177, currently in Phase 1 trials targeting solid tumors.
Oncorus Appoints New COO to Drive Growth
Oncorus, Inc. (Nasdaq: ONCR) announces the appointment of Steve Harbin as Chief Operating Officer and Chief of Staff. With over 30 years in biotechnology and pharmaceuticals, including key roles at Moderna, Harbin is expected to lead operational scale-up and the expansion of Oncorus’ manufacturing capabilities. The company is advancing its lead viral immunotherapy candidate, ONCR-177, through clinical trials while preparing to nominate additional candidates. This leadership change could enhance Oncorus' infrastructure during a critical phase in its development.
Oncorus, Inc. (Nasdaq:ONCR) announced that CEO Theodore A. Ashburn will participate in two investor conferences. The 32nd Annual Piper Sandler Virtual Healthcare Conference runs from December 1-3, 2020, with a pre-recorded presentation available online. Additionally, Ashburn will present live at the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020, at 9:40 a.m. ET. Oncorus is focused on innovative viral immunotherapies for cancer treatment, including its lead program, ONCR-177, aimed at enhancing therapeutic impact while minimizing systemic toxicity.
Oncorus, a viral immunotherapies company, announced that CEO Theodore A. Ashburn will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:50 pm GMT (10:50 am ET). The presentation will focus on Oncorus’s innovative approaches in cancer treatment, particularly their lead oHSV program, ONCR-177, designed for direct tumor administration to enhance therapeutic efficacy while minimizing systemic exposure. A live webcast will be accessible on Oncorus's website, with a replay available for 90 days.
Oncorus, a viral immunotherapies company, reported its third quarter 2020 results and outlined significant achievements. In October, it completed an IPO, raising $98.4 million in gross proceeds. The company initiated a Phase 1 clinical trial for its lead candidate, ONCR-177, targeting solid tumors, in collaboration with Merck to test ONCR-177 alongside KEYTRUDA®. As of September 30, 2020, Oncorus had $54.0 million in cash, projecting sufficient capital to fund operations into 2023. However, the company reported a net loss of $22.4 million for the quarter.
Oncorus, a clinical stage biopharmaceutical company specializing in viral immunotherapies for cancer treatment, announced that its CEO, Theodore A. Ashburn, will present at the Chardan 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:15 p.m. ET. The company is advancing its lead candidate, ONCR-177, which utilizes a proprietary oncolytic HSV-1 platform designed to target and destroy tumor cells while enhancing the immune response against cancers. For more information, visit www.oncorus.com.
Oncorus, a clinical stage biopharmaceutical company, priced its initial public offering (IPO) at $15.00 per share, raising approximately $87 million. A total of 5,800,000 shares are being offered, with an additional 870,000 shares available to underwriters. Trading is set to begin on the Nasdaq under ticker symbol 'ONCR' on October 2, 2020, with the offering closing around October 6, 2020. Jefferies, Evercore ISI, and Piper Sandler are acting as joint book-running managers. The funds raised aim to further develop Oncorus' innovative viral immunotherapy treatments for cancer.
FAQ
What is the market cap of Oncorus (ONCR)?
